pharma · Obesity, Overweight · Type 2 Diabetes
Eli Lilly Co.
Eli Lilly Co is a pharma organization headquartered in EU. Primary therapeutic focus areas include Obesity, Overweight, Type 2 Diabetes, Ulcerative Colitis, Type 2 Diabetes Mellitus, Breast Cancer. NovaPharmaNews links 1
Phase 3 · small molecule · Obesity
Tirzepatide is a small-molecule subcutaneous injection developed by Eli Lilly for the treatment of obesity and weight-related comorbidities. The drug is currently in Phase 3 development, with an active trial (SURMOUNT-ADOLESCENTS-2, NCT 2023-507655-30-00) evaluating efficacy and safety in adolescents. Tirzepatide has a
Internal code I8F-MC-GPIX
Tirzepatide is a small-molecule subcutaneous injection developed by Eli Lilly for the treatment of obesity and weight-related comorbidities. The drug is currently in Phase 3 development, with an active trial (SURMOUNT-ADOLESCENTS-2, NCT 2023-507655-30-00) evaluating efficacy and safety in adolescents. Tirzepatide has already achieved regulatory approval in multiple jurisdictions: the European Union (approved 29 January 2026), Japan (approved December 2024), and the United States (NDA applications 215866 and 217806). The compound is marketed under the brand name MOUNJARO and is classified within the Alimentary tract and metabolism therapeutic category (ATC A10). Eli Lilly's strategy encompasses expansion into the adolescent population through the SURMOUNT-ADOLESCENTS-2 trial, broadening the drug's clinical utility beyond adult obesity indications. The Phase 3 trial employs a randomized, double-blind, placebo-controlled design to establish efficacy and safety endpoints in this younger demographic. Current regulatory status indicates active development in the adolescent indication, with approvals already secured in major markets for existing indications.
Obesity represents a significant unmet medical need globally, with rising prevalence in both adult and adolescent populations and substantial associated comorbidities including cardiovascular disease, type 2 diabetes, and metabolic dysfunction. The adolescent obesity market remains underserved, with limited pharmacological treatment options approved specifically for this age group, creating a substantial clinical gap. Tirzepatide's expansion into adolescents addresses this unmet need and represents a meaningful commercial opportunity, as successful approval could establish a new standard of care in pediatric weight management. The drug's mechanism—dual GLP-1 and GIP receptor agonism—differentiates it from earlier-generation weight loss agents and positions it competitively against agents like SAXENDA (liraglutide) and other metabolic therapies. Market relevance is heightened by the chronic nature of obesity and the potential for long-term treatment, supporting substantial peak sales projections. The competitive landscape includes multiple approved agents across different therapeutic classes (DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists), yet tirzepatide's dual mechanism and demonstrated efficacy in adults create differentiation. Regulatory approvals in the EU, Japan, and US validate the drug's safety and efficacy profile, reducing development risk for the adolescent indication and supporting accelerated market penetration.
Drug Class: Dual GLP-1/GIP receptor agonist; Alimentary tract and metabolism agent (ATC A10).
Modality: Small-molecule subcutaneous injection.
Route of Administration: Subcutaneous injection, administered once weekly.
Brand Name: MOUNJARO (tirzepatide).
Mechanism of Action: Not yet disclosed in the provided facts; however, dual GLP-1 and GIP receptor agonism is implied by therapeutic classification.
Target: Not yet disclosed.
Related Therapies: Earlier-generation GLP-1 receptor agonists (e.g., SAXENDA/liraglutide); DPP-4 inhibitors (TRAJENTA, ONGLYZA, NESINA, VIPIDIA); SGLT2 inhibitors (FORXIGA, INVOKANA); other weight loss agents.
First Approval: United States (NDA 215866, NDA 217806); European Union (29 January 2026, EMEA/H/C/005620, MAH Eli Lilly Nederland B.V.); Japan (December 2024).
Patent Status: Not yet disclosed.
Also known as: obesity, obesity disease
A disorder involving an excessive amount of body fat.
ClinicalTrials.gov lists 50 registered studies for Obesity (Disorder) (AACT aggregate).
Phase breakdown: NA (46), PHASE4 (3), PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0011122), Orphanet — obesity disorder, NCT03412149, NCT06787001, NCT06852391, NCT06881485, NCT06911918, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
SURMOUNT-ADOLESCENTS-2 Active
Phase 3 randomized, double-blind, placebo-controlled trial evaluating tirzepatide efficacy and safety in adolescents with obesity and weight-related comorbidities (NCT 2023-507655-30-00).
Japan Approval
Tirzepatide approved in Japan (PMDA).
EU Approval
Tirzepatide approved in the European Union (EMEA/H/C/005620, MAH Eli Lilly Nederland B.V.).
US Approval
Tirzepatide approved in the United States (NDA 215866, NDA 217806).
The obesity and metabolic disease treatment landscape includes multiple approved agents across distinct therapeutic classes. SAXENDA (liraglutide, Teva Pharma GmbH) is an approved GLP-1 receptor agonist for weight management, representing the most direct competitor in the incretin-based therapy space. DPP-4 inhibitors—including TRAJENTA (linagliptin, Boehringer Ingelheim), ONGLYZA (saxagliptin, AstraZeneca), NESINA (alogliptin, Lacuna Pharma), and VIPIDIA (vildagliptin, Takeda)—are approved agents that modulate incretin signaling but with different mechanisms and clinical profiles. SGLT2 inhibitors such as FORXIGA (dapagliflozin, AstraZeneca) and INVOKANA (canagliflozin, Teva Pharma) address metabolic dysfunction through distinct renal mechanisms. Older agents including ACTOS (pioglitazone, Alphapharm) and REPAGLINIDE SUN (repaglinide, Teva Pharma) represent earlier-generation metabolic therapies. Tirzepatide's dual GLP-1/GIP receptor agonism differentiates it mechanistically from single-target agents, potentially offering superior efficacy in weight reduction and metabolic control. The drug's approval status in major markets (US, EU, Japan) and active Phase 3 development in the adolescent population position it as a competitive threat to existing weight loss agents, particularly SAXENDA, while its mechanism may offer advantages over DPP-4 inhibitors and SGLT2 inhibitors in specific patient populations.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| TRAJENTA | Boehringer Ingelheim Pty Ltd | — | approved |
| ACTOS | Alphapharm Pty Ltd | — | approved |
| ONGLYZA | AstraZeneca | — | approved |
| VIPIDIA | Takeda | — | approved |
| REPAGLINIDE SUN | Teva Pharma GmbH | — | approved |
| NESINA | Lacuna Pharma Pty Ltd | — | approved |
| ZYNQUISTA | LEXICON PHARMACEUTICALS, INC. | — | approved |
| SAXENDA | Teva Pharma GmbH | — | approved |
| FORXIGA | AstraZeneca | — | approved |
| QTRILMET | Takeda | — | approved |
| TRAZEC | Teva Pharma GmbH | — | approved |
| INVOKANA | Teva Pharma GmbH | — | approved |
| SIBUTRAMINE | — | Monoamine transporter inhibitor | Approved |
| SETMELANOTIDE ACETATE | — | Melanocortin receptor 4 agonist | Approved |
| SETMELANOTIDE | — | Melanocortin receptor 4 agonist | Approved |
| RIMONABANT | — | Cannabinoid CB1 receptor antagonist | Approved |
| PHENTERMINE HYDROCHLORIDE | — | Norepinephrine transporter releasing agent | Approved |
| PHENTERMINE | — | Norepinephrine transporter releasing agent | Approved |
| PHENDIMETRAZINE TARTRATE | — | Norepinephrine transporter inhibitor | Approved |
| ORLISTAT | — | Pancreatic lipase inhibitor | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States: Tirzepatide approved; NDA applications 215866 and 217806 (sponsor: ELI LILLY AND CO).
European Union: Approved 29 January 2026; EMEA/H/C/005620; Marketing Authorization Holder: Eli Lilly Nederland B.V.
Japan (PMDA): Approved December 2024.
China (NMPA): Regulatory status not yet disclosed.
Adolescent Indication: Phase 3 trial (SURMOUNT-ADOLESCENTS-2, NCT 2023-507655-30-00) currently active; regulatory pathway and expected approval timeline not yet disclosed.
Tirzepatide is approved for the treatment of obesity and weight-related comorbidities in adults. A Phase 3 trial (SURMOUNT-ADOLESCENTS-2) is currently evaluating its efficacy and safety in adolescents with obesity and weight-related comorbidities.
Yes, tirzepatide is approved in the United States under NDA applications 215866 and 217806, sponsored by Eli Lilly and Co.
Yes, tirzepatide was approved in the European Union on 29 January 2026 under EMEA/H/C/005620, with Eli Lilly Nederland B.V. as the Marketing Authorization Holder.
Yes, tirzepatide was approved in Japan in December 2024 by the PMDA.
Tirzepatide is marketed under the brand name MOUNJARO.
Tirzepatide is administered as a subcutaneous injection once weekly.
Tirzepatide is developed and sponsored by Eli Lilly Co., with Eli Lilly Nederland B.V. serving as the Marketing Authorization Holder in the European Union.
The mechanism of action is not yet disclosed in available facts; however, tirzepatide is classified as a dual GLP-1 and GIP receptor agonist based on its therapeutic category.
Tirzepatide is in Phase 3 development for the adolescent obesity indication, with the SURMOUNT-ADOLESCENTS-2 trial (NCT 2023-507655-30-00) currently active.
SURMOUNT-ADOLESCENTS-2 is a randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of tirzepatide once weekly versus placebo for obesity and weight-related comorbidities in adolescents.
Tirzepatide is classified within the Alimentary tract and metabolism therapeutic class (ATC A10).
Main competitors include SAXENDA (liraglutide, a GLP-1 agonist), DPP-4 inhibitors (TRAJENTA, ONGLYZA, NESINA, VIPIDIA), and SGLT2 inhibitors (FORXIGA, INVOKANA). Tirzepatide's dual GLP-1/GIP mechanism differentiates it from these single-target agents.
Tirzepatide is not yet approved for adolescents; the SURMOUNT-ADOLESCENTS-2 Phase 3 trial is currently evaluating its safety and efficacy in this population.
Tirzepatide is a small-molecule subcutaneous injection.
No partner or licensee is disclosed in the available facts; Eli Lilly Co. is the sole sponsor.
The expected timeline for trial completion and results is not yet disclosed.
Tirzepatide addresses the significant unmet need for pharmacological treatment of obesity in adolescents, a population with limited approved therapeutic options and rising obesity prevalence with associated comorbidities.
I8F-MC-GPIX → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Eli Lilly's Phase 3 expansion of tirzepatide into the adolescent obesity indication addresses a significant clinical gap and represents a high-value label expansion opportunity. Successful approval would establish tirzepatide as a foundational therapy across the lifespan, supporting long-term patient relationships and chronic treatment paradigms. The company's multi-market approval strategy (US, EU, Japan) demonstrates confidence in the drug's profile and positions tirzepatide for rapid global penetration.
Competitive Implications: Tirzepatide's dual GLP-1/GIP mechanism and demonstrated efficacy in adults create a competitive moat against single-target agents like SAXENDA. Approval in adolescents would establish a first-mover advantage in this underserved population, potentially displacing older agents (ACTOS, DPP-4 inhibitors) and limiting SAXENDA's market share. The drug's once-weekly dosing and subcutaneous route align with patient preferences relative to oral alternatives.
Future Catalysts: SURMOUNT-ADOLESCENTS-2 trial completion and regulatory submissions in major markets; potential label expansions to additional weight-related comorbidities; real-world evidence generation post-approval; pricing and reimbursement negotiations in key markets.
Expected Milestones: Phase 3 trial data readout (timing not yet disclosed); regulatory submissions and approvals in adolescent indication; potential pediatric extension studies; market launch in adolescent population.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.